Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
MACROGOL 3350
Bayer Limited
5.9 Grams
Powder for Oral Solution
2008-11-03
IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. NO.540 OF 2007) PA1410/055/002 Case No: 2055535 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to BAYER LIMITED THE ATRIUM, BLACKTHORN ROAD, DUBLIN 18, IRELAND an authorisation, subject to the provisions of the said Regulations, in respect of the product TRANSIPEG 5.9G POWDER FOR ORAL SOLUTION IN SACHET The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 30/01/2009. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 30/01/2009_ _CRN 2055535_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Transipeg 5.9g powder for oral solution in sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains 5.9g of Macrogol 3350. Excipients: Transipeg 5.9 g contains 290 mg of sodium and 40 mg of potassium per sachet as well as aspartame (E591) and sucrose. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Powder for oral solution in sachet. White or almost white powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Symptomatic treatment of constipation in adults. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The posology is from 1 to 2 sachets daily in one intake, taken in the Read the complete document